Flamma SpA, a CDMO that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, recently broke ground for a new R&D building in Chignolo d’Isola, Bergamo, Italy.
The expansion at Flamma’s headquarters will allow the company to quadruple its R&D space. The new facility will accommodate 50 additional employees, additional R&D and analytical development laboratories, as well as offices and meeting rooms. Additionally, there will be a lab for high containment and special chemistries.
During the Covid-19 crisis of 2020, teams in Italy and China worked to continue production of important molecules critical to helping fight the virus.
The new R&D building will complement the R&D work being done at Flamma USA in Malvern, PA. The team in the U.S. also continues to grow as more projects come on board.
